Replicative Capacity of β-Cells and Type 1 Diabetes|
The reviewers highlight features of the β-cell, including it being part of a pancreatic islet, a mini-organ that is highly vascularized and highly innervated, and efforts to promote β-cell proliferation. [J Autoimmun] Abstract
Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
Allergan Receives CHMP Positive Opinion for ENZEPI® (Pancrelipase) for Patients with Exocrine Pancreatic Insufficiency (EPI)|
Allergan plc announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a Positive Opinion for the Marketing Authorisation of ENZEPI® in the European Union. [Allergan plc] Press Release
Dr. Gordon Weir, Co-Head of Section on Islet Cell and Regenerative Biology at Joslin, to Receive the Albert Renold Award for His Significant Impact as a Mentor from the American Diabetes Association
Gordon Weir, M.D., Diabetes Research and Wellness Foundation Chair, Co-Head of Section on Islet Cell and Regenerative Biology at Joslin Diabetes Center and Professor of Medicine at Harvard Medical School, has been selected as the recipient of the American Diabetes Association’s 2016 Albert Renold Award. [Joslin Diabetes Center] Press Release
Sanofi US Collaborates with Duke University and Massachusetts General Hospital on Big Data and Type 2 Diabetes
Sanofi US announced collaborations with the Duke Clinical Research Institute and, separately, with the Center for Assessment Technology and Continuous Health at Massachusetts General Hospital. The collaborations are designed to create new tools that will help predict how people living with type 2 diabetes adhere to their medication. [Sanofi US] Press Release
Echo Therapeutics Announces Significant Progress in Key Development Milestones
Echo Therapeutics, Inc. announced important advances in its next generation continuous glucose monitoring system and its progress toward commercialization in China. Important advancements were made in the NextGen sensor element, hydrogel and other key components of the company’s highly disruptive technology to the episodic, needle-based glucose monitoring business. [Echo Therapeutics] Press Release
From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.